OPTIMIZING ANTIRETROVIRAL THERAPY IN HIV-INFECTED CHILDREN AND ADOLESCENTS

优化感染艾滋病毒的儿童和青少年的抗逆转录病毒治疗

• 批准号: 7717173
• 负责人: NATELLA Y RAKHMANINA
• 金额: $ 61.73万
• 依托单位: CHILDREN'S RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7717173
• 关键词: ABCB1 gene; Address; Adolescent; CD4 Lymphocyte Count; CYP2C19 gene; CYP3A4 gene; CYP3A5 gene; Child; Childhood; Classification; Clinical; Computer Retrieval of Information on Scientific Projects Database; Dose; Drug Kinetics; Funding; Genes; Genetic; Genetic Variation; Goals; Grant; HIV Infections; Institution; Investigation; Outcome; Outcome Measure; Patients; Pharmaceutical Preparations; Pharmacogenetics; Prevalence; Protease Inhibitor; Protocols documentation; Reaction; Research; Research Personnel; Resources; Source; Toxic effect; United States National Institutes of Health; Viral Load result; antiretroviral therapy; base; cohort; improved; viral RNA; virtual

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The long-term goal of the research investigation is to improve dosing of protease inhibitors (PIs) in HIV-infected children, leading to improved outcome and decreased adverse drug reactions. In order to do so, the protocol addresses the following specific aims: Specific Aim 1: Determine the prevalence of genetic variations in CYP2C19, CYP3A4, CYP3A5, and MDR-1 genes in a cohort of children and adolescents with HIV infection. Specific Aim 2: Evaluate the relationship of this genetic variability to the pharmacokinetic parameters (Cmin, Cmax, AUC) and toxicity (graded by the DAIDS classification) of protease inhibitors in pediatric patients with HIV infection. Specific Aim 3: Evaluate the impact of dose adjustment of protease inhibitors based on pharmacogenetic profile and virtual inhibitory quotient (VIQ) on clinical outcome (measured by HIV-RNA viral load and CD4+ cell count changes) and toxicity (graded by the DAIDS classification) in pediatric patients with HIV infection.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 研究研究的长期目标是改善艾滋病毒感染儿童蛋白酶抑制剂（PIS）的剂量，从而改善结果并减少不良药物反应。 为此，协议解决了以下特定目的： 具体目标1：确定CYP2C19，CYP3A4，CYP3A5和MDR-1基因中遗传变异的患病率在患有HIV感染的儿童和青少年中。 具体目的2：评估这种遗传变异性与药代动力学参数（CMIN，CMAX，AUC）和毒性（通过daids分类分级）的蛋白酶抑制剂在儿科感染患者中的关系。 具体目的3：根据药物遗传学特征和虚拟抑制剂（VIQ）（通过HIV-RNA病毒载量和CD4+细胞计数变化）和毒性（通过DAIDS分类分级），评估蛋白酶抑制剂对蛋白酶抑制剂的剂量调整对临床结局的影响。